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Abstract: The antihypertensive activity of olive leaf extract (OLE), a natural 
antioxidant is recognized, but its influence on the cardiovascular system when 
administered in a high dose has not yet been investigated. The aim of the pre-
sent study was to determine the acute effects of excessive intake of standard-
ized OLE on blood pressure, heart rate and oxidative status in both spontane-
ously hypertensive rats and normotensive Wistar rats. The systolic arterial 
pressure and heart rate were measured using a tail-cuff and pneumatic pulse 
detector before and 60 and 120 min after intragastric OLE administration. The 
activities of catalase, glutathione peroxidase, superoxide dismutase (SOD) and 
glutathione reductase in erythrocytes, as well as lipid peroxidation in plasma 
(pTBARS) were measured spectrophotometrically at the same time points. A 
high-dose of OLE did not influence blood pressure, heart rate or pTBARS in 
normotensive rats, while the SOD, catalase and glutathione reductase activities 
were significantly increased. The same dose significantly decreased blood pres-
sure in hypertensive rats, but increased the pTBARS and SOD activity. Exces-
sive oral intake of OLE induced moderate hypotensive effects only in spon-
taneously hypertensive rats, suggesting the absence of harmful hemodynamic 
effects after an oral overdose in both rat strains. However, its pro-oxidative role 
when given in a high dose in hypertensive organisms should not be neglected.  
Keywords: Olea europaea L.; hypertension; acute oral toxicity; spontaneously 
hypertensive rat; oxidative stress. 
INTRODUCTION 
Hypertension is the most important cardiovascular risk factor worldwide, 
contributing nearly 50 % to prevalent coronary heart disease and approximately 
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70 % of prevalent cerebrovascular disease burdens.1 It is widely known that 
dietary changes play an important role in managing blood pressure. A number of 
studies showed that the Mediterranean food pattern plays a significant role in the 
prevention of cardiovascular disease.2 It was reported that olive oil represents a 
key healthy component of Mediterranean diet and that dietary intake of virgin 
olive oil, thanks to its minor constituents, exhibits cardio-protective effects.3 
Moreover, there is evidence that daily doses of blood pressure medication could 
be reduced during olive oil diet. This finding could be partly attributed to the 
polyphenols, which enhance nitric oxide (NO) concentrations and may help vaso-
dilatation, which reduces blood pressure.4 
The results of recent investigations suggested beneficial effects of phenolic-
rich olive leaf extracts (OLE) as dietary supplements in modifying cardiovascular 
risk biomarkers, such as blood pressure, hyperglycemia, oxidative stress and inf-
lammation, as well as in improving vascular function and lipid profiles.5 Several 
preclinical studies confirmed the antihypertensive activity of OLE or its active 
constituents on different experimental models,6,7 and the mechanisms of this 
action are continuously being studied. Moreover, the dual effect of OLE in both 
reducing blood pressure and improving lipid profile was presented as the result of 
clinical trials.8,9 OLE contains large amounts of potentially useful phytoche-
micals, many of the same phenolics as in olive oil, but in much higher concentra-
tions.10 Its chemical content makes olive leaf one of the most potent natural anti-
oxidants. The main constituent is oleuropein, an iridoide monoterpene. This com-
pound, obtained by decoction of olive leaves, has been recognized as one of the 
constituents responsible for vasodilating activity on isolated rat aorta.11 More-
over, as a constituent of aqueous OLE, it showed high angiotensin-converting- 
-enzyme (ACE) inhibitor activity.12 Furthermore, olive leaf contains triterpenes 
(oleanolic, ursolic and maslinic acid) with confirmed antihypertensive, anti-athe-
rosclerotic and antioxidant activity on a Dahl salt-sensitive, insulin-resistant 
genetic model of hypertension.13 Flavonoids, including luteolin, apigenin and 
quercetin, are also important antihypertensive components of OLE.14,15 The 
beneficial properties of olive leaf are further enhanced by the good absorption of 
its phenolic constituents and their bioavailability, which is a necessary pre-con-
dition for its bioactivity.16 
Herbal medicines are classified as dietary supplements or foods rather than 
drugs and do not require approval by regulatory drug agencies to be marketed. 
Hence, their efficacy and potential toxicity is not evaluated thoroughly. Due to 
traditional use, there is general opinion that these products are safe and harmless. 
However, many of them previously used in other forms, a diluted tea for example, 
may now be available as concentrated and potent extract formulations and thus 
potentially harmful.17 Based on the available safety/toxicity studies of total olive 
leaf extract and its constituents, and the history of the use of the components of 
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the extract through table olives, olive products and olive oil, the consumption of 
OLE could be considered as safe.18 A recent investigation showed that no report 
has indicated the negative effects of recommended, moderate doses of OLE over 
longer periods. However, there is an issue with many different commercial extracts 
of olive leaf since the composition of OLE in these products varies. There is data 
available that concerns the correct dosage and the side effects from long-term 
intake of mega doses of OLE. Recently, findings regarding the effects of diffe-
rent concentrations of OLE on the function of mice liver over the course of 14 
weeks revealed that alanine aminotransferase and alkaline phosphatase serum 
enzyme activities increased significantly, and hepatic fibrosis was observed in 
the groups in which higher (0.5 and 0.75 %) OLE concentrations were used. All 
the groups exposed to OLE exhibited hyperplasia of the bile ducts, cholestasis, 
and hepatocyte necrosis.19 It was also shown that feeding doses of 0.2–0.9 % of 
OLE to Wistar rats for a period of 6 weeks may induce hematological, bioche-
mical as well as hepatocellular and renal abnormalities of experimental ani-
mals.20 Hitherto, the effects of acute excessive intake of concentrated, oleuro-
pein-rich OLE have not been seriously investigated, in particular effects on the 
cardiovascular system. Hence, the safety of high-dose intake of this “cardiovas-
cular friendly” natural product has been quite neglected. 
The aim of the present study was to investigate the acute in vivo blood 
pressure effects of high doses of this natural antihypertensive agent administered 
to spontaneously hypertensive and to normotensive rats. In addition, the effects 
of high-dose of this natural antioxidant on the plasma lipid peroxidation and anti-
oxidant defense system in erythrocytes of the both strains of experimental rats 
were investigated.  
EXPERIMENTAL 
Chemicals 
Olive leaf extract EFLA® 943, standardized to 18–26 % of oleuropein, was purchased 
from Frutarom Switzerland Ltd. (Wadenswil, Switzerland). The extract was manufactured 
from the dried leaves of Olea europaea L., applying an ethanol (80 vol. %) extraction proce-
dure. After a patented filtration process (EFLA® Hyperpure), the crude extract was dried. The 
stability and microbiological purity of the extract were confirmed by the manufacturer. A 
comprehensive phytochemical analysis was performed previously.21 In this study, the same 
batch of EFLA® 943 was used. It was kept in sealed microtubes, stored at room temperature 
and protected from light until use. All other chemicals used for biochemical analyses were 
obtained from Sigma (St Louis, MO, USA).  
Animals 
Male, adult, age matched spontaneously hypertensive rats (SHR) and Wistar (normo-
tensive) rats, weighing about 280–330 g, were bred in the Institute for Medical Research, 
University of Belgrade. The rats were housed 4 in a cage under constant environmental 
conditions (20–24 °C; 12h light-dark cycle), and fed ad libitum with a standard chow for 
laboratory rats (Veterinary Institute, Subotica, Serbia). 
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The experimental protocol was approved by the Ethical Committee of the Institute for 
Medical Research, University of Belgrade, Serbia (No. 0316-1/11) according to the National 
Law on Animal Welfare (“Official Gazette of RS” No. 6/10, in Serbian) that is consistent with 
guidelines for animal research and principles of the European Convention for the Protection of 
Vertebrate Animals Used for Experimental and Other Purposes (Official Daily N. L 358/1- 
-358/6, 18, December 1986) and EU Directive on the protection of animals used for scientific 
purposes (Directive 2010/63). 
Acute oral toxicity study 
Acute oral toxicity test was run strictly in accordance with OECD Guidelines for the 
Testing of Chemicals, Section 4: Health Effects: Test No. 423: Acute Oral toxicity – Acute 
Toxic Class Method, which was described in details in a recent publication.22 Briefly, three 
male and three female young adult Wistar rats (ten weeks old, weight 190 to 230 g) were 
fasted 16 h before the experiment. A single dose of 2000 mg kg-1 b.w. of OLE was admi-
nistered intragastrically (i.g.) through a metal gavage tube. Three hours after treatment, diet 
was available ad libitum. The rats were observed for abnormal behavioral signs, somnolence, 
dizziness, restlessness, neurological signs, respiratory distress or mortality, and weighed daily 
after administration of OLE. At the end of the test (day 14), the rats were sacrificed by cer-
vical dislocation, and gross pathological changes in the main organs (brain, liver, kidney, 
spleen, gastric and intestinal mucosa) were evaluated.  
Blood pressure and heart rate measurements  
The systolic blood pressure and heart rate were indirectly measured using a tail-cuff, 
pneumatic pulse detector and a direct recorder (Physiograph Four, Narco Bio-System, Hous-
ton, TX, USA). Before the experiment, two separate baseline determinations of body weight 
and systolic blood pressure were made for all experimental animals over a span of 4 days and 
the rats were divided into six groups, three groups for each rat species (8 rats per group).  
The cardiovascular effect of a high dose (2000 mg kg-1, dissolved in 0.5 mL of tap 
water) of i.g.-administered OLE was investigated. The study was performed on six experi-
mental groups according to strains and treatment they received as follows: W Control – Wistar 
rats received tap water (0.5 mL i.g.); WOLE60′ and WOLE120′ – Wistar rats in which the 
measurements of blood pressure, heart rate and oxidative stress parameters were performed 60 
or 120 min after OLE administration, respectively; SH Control – spontaneously hypertensive 
rats (SHR) received tap water (0.5 mL i.g.); SHOLE60′ and SHOLE120′ – SHR received OLE 
and the measurement of hemodynamic and oxidative stress parameters were performed in 60 
or 120 min after OLE administration, respectively. After cardiovascular measurement, ani-
mals were anaesthetized (35 mg kg-1 sodium pentobarbital; i.p.) and blood samples were col-
lected immediately. At the end of the experiment, the animals were sacrificed by a pento-
barbital overdose injection. 
Biochemical measurements  
Blood samples were centrifuged at 4 °C at 3000 rpm for 15 minutes and erythrocytes 
were separated. Hemoglobin (Hb) content was estimated by the method of Drabkin and 
Austin.23  
All spectrophotometric analyses of the activities of the antioxidant enzymes in the 
plasma or erythrocytes were performed using an Ultrospec 3300 pro UV/Vis spectrophoto-
meter (Amersham Biosciences Corp., USA).  
The plasma thiobarbituric acid reactive substances (pTBARS), as a marker of plasma 
lipid peroxidation, were measured using 2-thiobarbituric acid (2,6-dihydrooxypyrimidine-2- 
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-thiol; TBA). An extinction coefficient of 156,000 M-1 cm-1 was used for the calculation24 and 
level of pTBARS is expressed as nmol mL-1 plasma.  
The endogenous antioxidant status of the red blood cell was investigated in all experi-
mental groups. The activity of catalase (CAT) was determined according to the procedure of 
Beutler by following the absorbance of hydrogen peroxide at 230 nm.25 The activity of catal-
ase is expressed as U g-1 of hemoglobin where one unit of CAT activity is defined as mmol 
H2O2 min-1.  
Glutathione reductase (GR) activity was estimated according to the method of Glatzle.26 
The GR activity is expressed as U g-1 hemoglobin, where one unit of GR activity is defined as 
(mmol oxidized NADPH) min-1 g-1 hemoglobin.  
Glutathione peroxidase (GSH-Px) activity was determined according to the previously 
described method suggested by Paglia and Valentine.27 One unit of GSH-Px activity is defined 
as (μmol oxidized NADPH) min-1.  
Activity of superoxide dismutase (SOD) was measured spectrophotometrically using a 
previously described method of epinephrine auto-oxidation28 and is expressed as U g-1 Hb.  
Statistical analysis  
The data are given as mean ± SEM. One-way analysis of variance (ANOVA) was used 
for comparison between the experimental groups of the same rat strain, while the Fisher LSD 
test was performed for post hoc multiple comparisons. Comparison between normotensive 
Wistar control rats and control SHRs was made using Student’s t-tests. P values less than 0.05 
were considered as significant (Statistica 8.0 for Windows). 
RESULTS 
Acute oral toxicity 
For the evaluation of acute oral toxicity of the OLE, a single dose (2000 mg 
kg–1) was orally administered to Wistar rats. During the study period of two 
weeks, no death occurred in the treated animals. The body weight did not vary 
after drug administration, and the autoptic analysis failed to show appreciable 
macroscopic alterations of the internal organs. The absence of adverse effects at 
concentrations as high as 2000 mg kg–1 b.w. did not allow the calculation of the 
median lethal dose (LD50) value. In principle, the method used is not intended to 
allow the calculation of a precise LD50 value. Exceptionally, and only when jus-
tified by specific regulatory needs, may the use of an additional upper dose level 
of 5000 mg kg–1 b.w. be considered. In accordance with OECD Guidelines and 
for concern of animal welfare, the testing of animals in GHS Category 5 ranges 
(2000–5000 mg kg–1) is discouraged. Thus, the standardized OLE EFLA® 943 
used in this study belongs to the so-called Category 5 or unclassified.  
Hemodynamic and oxidative stress parameters after excessive oral intake of OLE 
As expected, a significant difference (P < 0.001) was recorded in the systolic 
blood pressure and heart rate values between W Control and SHR Control (Fig. 
1). Orally ingested OLE, even in high doses, did not influence the blood pressure 
of normotensive experimental animals. The same dose had reduced the blood 
pressure in SHR 60 and 120 min after the treatment by 20 and 13 %, respectively 
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(Fig. 1A). The heart rate remained unaffected in the Wistar strain of rats. In the 
hypertensive rats, the heart rate was significantly higher in the SHOLE120′ than 
in the SHOLE60′ group, but there was no significant difference in comparison to 
the SH control group (Fig. 1B). 
Fig. 1. Effect of Olea europaea L. leaf 
extract (OLE, 2000 mg kg-1; i.g.) on: A) 
systolic arterial pressure (SAP, 1 mm Hg =  
= 133.3 Pa) and B) heart rate (HR) of 
normotensive Wistar (W) rats and spont-
aneously hypertensive rats (SHR). WCon-
trol – W rats treated with water; WOLE60′ 
– W rats, 60 min after OLE treatment; 
WOLE120′ – W rats, 120 min after OLE 
treatment; SHControl – SHR treated with 
water; SHOLE60′ – SHR, 60 min. after 
OLE treatment; SHOLE120′ – SHR, 120 
min. after OLE treatment; *P < 0.05 and 
**P < 0.01, indicates statistical significance 
difference compared to the respective con-
trol; ###P < 0.001, the difference between 
SHControl and WControl groups; § indi-
cates the difference (P < 0.05) between 
SHOLE120′ and SHOLE60′. 
In normotensive rats, pTBARS levels were unchanged in both the OLE 
treated groups compared to the control. However, the level of lipid peroxidation 
in the plasma of hypertensive animals increased significantly (P < 0.05) after 
excessive oral intake of OLE at both the examined time points (Fig. 2). 
The results of the determination of the activity of four anti-oxidative enzymes 
at three time points, before, 60 and 120 min after OLE administration, are pre-
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sented in Fig. 3. It is evident that activities of CAT and GR were significantly 
higher in the SH Control in comparison to the W Control group. After OLE 
administration to normotensive Wistar rats, the activities of CAT, SOD and GR 
(Fig. 3A, C and D) were significantly higher in comparison to the W Control 
group, while the activity of GSH-Px (Fig. 3B) was significantly lower. Adminis-
tration of OLE did not influence the activities of CAT, GSH-Px and GR (Fig. 3A, 
B and D) in SHR, but the SOD activity was markedly increased 120 min after 
OLE treatment (Fig. 3C). 
Fig. 2. Effects of Olea europaea L. leaf 
extract (OLE, 2000 mg kg-1; i.g.) on the 
plasma concentration of thiobarbituric acid 
reactive substances (pTBARS) of normo-
tensive Wistar (W) rats and spontaneously 
hypertensive rats (SHR). WControl – W 
rats treated with water; WOLE60′ – W rats, 
60 min after OLE treatment; WOLE120′ – 
W rats 120 min after OLE treatment; 
SHControl – SHR treated with water; 
SHOLE60′ – SHR, 60 min after OLE treat-
ment; SHOLE120′ – SHR, 120 min after 
OLE treatment; * indicates statistical sig-
nificance (P < 0.05) of the difference com-
pared to the respective control. 
DISCUSSION 
The purpose of this study was to evaluate the effects of excessive intake of 
standardized, oleuropein-rich olive leaf extract on blood pressure, heart rate and 
oxidative stress parameters in an established experimental model of genetically 
induced hypertension and in normotensive animals. To the best of our know-
ledge, this is the first in vivo study on the effects of a single high-dose OLE 
intake on lipid peroxidation and the activities of anti-oxidative enzymes in expe-
rimental hypertension. Thus, the results of this study represent a contribution to 
the overall safety assessment of Olea europaea-derived constituents as dietary 
supplements. 
As a basic step in this study, OLE was assessed for acute toxicity using the 
OECD Test Guideline 423 (Acute Oral Toxicity – Acute Toxic Class Method). 
The limit test was applied since data from the literature indicated that OLE is likely 
to be non-toxic. There are only few preclinical safety data for various olive leaf 
extracts and some incomplete toxicological data concerning the toxicity of oleu-
ropein. The LD50 of an extract of olive leaf was not precise when it was given intra-
peritoneally (i.p.) as a single dose of 1300 mg kg–1 or as dose of 3000 mg kg–1  
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Fig. 3. Effect of Olea europaea L. leaf extract (OLE, 2000 mg kg-1; i.g.) on: A) catalase 
(CAT), B) glutathione peroxidase (GSH-Px), C) superoxide dismutase (SOD) and D) 
glutathione reductase (GR) activity of normotensive Wistar (W) rats and spontaneously 
hypertensive rats (SHR). WControl – W rats treated with water; WOLE60′ – W rats, 60 min 
after OLE treatment; WOLE120′ – W rats, 120 min after OLE treatment; SHControl – SHR 
treated with water; SHOLE60′ – SHR, 60 min after OLE treatment; SHOLE120′ – SHR, 120 
min after OLE treatment; *P < 0.05, **P < 0.01 and ***P < 0.001 indicates statistical 
significance difference in the enzyme activity compared to the respective control. #P < 0.05 
and ##P < 0.01 represent the difference between SHControl and WControl groups; 
§§§ indicates the difference (P < 0.001) between WOLE120′ and WOLE60′. 
orally in mouse.29 The LD50 of a standardized aqueous olive pulp extract with 
hydroxytyrosol as the major constituent of biological significance was also 
reported to be greater than 2000 mg kg–1. Moreover, in a subchronic study, the 
no-observed-adverse-effect-level (NOAEL) of the same extract in rats was found 
to be 2000 mg kg–1 day–1. In developmental and reproductive toxicity studies, 
the studied extract did not cause toxicity at levels up to 2000 mg kg–1 daily.18 
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The results of the present acute oral toxicity study are consistent with previous 
findings, and confirmed that OLE EFLA® 943 is a safe material when admi-
nistered via oral gavage to rats in a single dose of 2000 mg kg–1. Clinical signs 
and gross findings of treatment-related adverse effects were not observed in the 
experimental rats. 
Different experimental models were used with the intention of investigating 
the hypotensive effect of total olive leaf extract. In a study by Khayyal et al., oral 
administration of OLE EFLA® 943 showed a dose dependent prophylactic effect 
against the rise in blood pressure induced by L-NAME.6 Commercial Olea euro-
paea L. leaf extract caused a concentration-dependent decrease in systolic left 
ventricular pressure and heart rate on isolated rabbit hearts.7 Nevertheless, no 
information is available regarding its high dose activity in normotensive con-
ditions and on an experimental model of genetically induced hypertension, such 
as SHR. Hence, the cardiovascular effect of excessive oral intake of OLE under 
hypertensive and normotensive conditions was the next step in the present study. 
It is known that oleuropein, the main component of OLE, is rapidly absorbed 
after oral administration, with maximum plasma concentration occurring after 
two hours.30 According to this data, the tested time intervals 60 and 120 min 
after OLE oral administration were chosen to obtain more detailed information 
on the dynamic changes in the cardiovascular parameters and the oxidative stress 
rate in blood. The results obtained revealed that orally ingested OLE, even at the 
high dose of 2000 mg kg–1, did not influence blood pressure and heart rate in 
normotensive experimental animals. The same dose reduced blood pressure by 
approximately 20 and 13 %, 60 and 120 min after the treatment, respectively. 
These findings could be explained by the dissimilar oxidative status in the nor-
motensive and hypertensive strains of the studied rats. Namely, while multiple 
diverse factors likely contribute to the development of hypertension, the patho-
genesis of this disease appears related, at least in part, to the development of a 
state of excessive oxidative stress. Local excessive superoxide production in the 
kidney, CNS, and vasculature, along with inflammatory activation, are central 
findings in hypertension models, including spontaneous hypertension in rats.31,32 
It was previously reported that either excess production of oxidants or a defi-
ciency of antioxidant systems may contribute to high blood pressure and the 
endothelium-dependent impairment of vascular relaxation in SHR.33 The results 
of the same study suggested that different antioxidants (ascorbic acid, aminotri-
azole and glutathione), administered in vivo as a single dose, significantly dec-
reased blood pressure in SHR, but not in Wistar Kyoto rats. In a previous study, 
the high anti-oxidative potential of OLE EFLA® 943 was confirmed in vitro 
using 2,2-diphenyl-1-picrylhydrazyl radical (DPPH•).34 Additional findings sug-
gested its strong anti-oxidative potential in vivo, in global cerebral ischemia and 
the reperfusion experimental model and in cold restraint stress-induced oxidative 
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changes in rat liver.34,35 According to these results and to the results from the 
present study, antihypertensive activity of OLE, at least partly, could be attri-
buted to its anti-oxidative potential.  
It was recently reported that extracts of Olea europaea L. leaves induced an 
increase in protein oxidation products in a concentration dependent manner.36 
The pro-oxidant activity of these plant extracts could be attributed to the unstable 
state of their phenoxyl radicals. Therefore, it was reasonable to expect pro-oxi-
dative effects of the high-dose OLE intake in the present study. It is obvious from 
the obtained results that OLE did not cause changes in plasma lipid peroxidation 
of normotensive animals. This could be explained by effective anti-oxidative 
protection in normotensive rats. Namely, increased CAT activity in response to 
enhanced H2O2 production (due to intensive SOD activity) probably could be 
responsible for the unchanged pTBARS. The antioxidant status in the SH Control 
group was compromised in the present study, as in the study by Yuan et al.37 The 
activities of catalase, which converts hydrogen peroxide into water and molecular 
oxygen, and glutathione reductase, which reduces the antioxidant glutathione 
from its oxidized to its reduced form, were significantly higher in SHR in com-
parison to the activities of these enzymes in normotensive Wistar rats before 
OLE administration. It is important to note that anti-oxidative enzymes have a 
bimodal behavior. In the short term, as was the case in some other experimental 
models,34,35 their activity decreases after acute oxidative damage, while in the 
long term, as in the case of genetically induced hypertension,13 it increases; in 
both cases, this may be an indicator of increased oxidative damage. Good oral 
bioavailability, good safety profile with limited side effects, efficacy in hyper-
tension originating from disparate etiologies, as well as limited potential for their 
pro-oxidative role are the recognized conditions for an optimal profile of natural 
antioxidant agent for anti-hypertensive therapy.38 Excessive oral intake of OLE 
reduced high blood pressure, but induced the lipid peroxidation process in the 
plasma of SHR, one and two hours after administration. In parallel, the activities 
of anti-oxidative enzymes, except SOD, remained unaffected in SHR.  
According to the results obtained in this study, it could be stated that OLE, 
like other dietary phenols, may be beneficial in the correct dosage. It could be 
considered for antihypertensive therapy in appropriate doses only, and its pro-
oxidative role when given in high dose (which could not be effectively buffered 
by increased SOD activity) in hypertensive organism should not be neglected.  
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И З В О Д  
ЕФЕКТИ ВИСОКЕ ДОЗЕ ЕКСТРАКТА ЛИСТА МАСЛИНЕ НА ХЕМОДИНАМСКЕ И 
ПАРАМЕТРЕ ОКСИДАТИВНОГ СТРЕСА КОД НОРМОТЕНЗИВНИХ И СПОНТАНО 
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Антихипертензивно дејство природног антиоксиданса, екстракта листа маслине 
(OLE) је познато, али до сада није испитиван његов утицај на кардиоваскуларни систем 
када се примењује у високој дози. Наш циљ је био да одредимо акутне ефекте преко-
мерног уноса стандардизованог екстракта на крвни притисак, срчану фреквенцију и 
оксидативни статус како код пацова са урођеном хипертензијом, тако и код Вистар 
пацова са нормалним артеријским притиском. Систолни притисак и фреквенција рада 
срца мерени су помоћу уређаја за индиректно регистровање крвног притиска у репној 
артерији, пре интрагастричног апликовања OLE, 60 и 120 min након давања. У истим 
временским тачкама, спектрофотометријски су мерене активности каталазе, глутатион- 
-пероксидазе, супероксид дисмутазе (SOD) и глутатион редуктазе у еритроцитима, као и 
липидна пероксидација у плазми (pTBARS). OLE у дози од 2000 mg kg-1 није утицао на 
крвни притисак, срчану фреквенцију и pTBARS код нормотензивних пацова, док су се 
активности SOD, каталазе и глутатион-редуктазе значајно повећале. Иста доза довела је 
до значајног смањења крвног притиска код хипертензивних животиња, али је повећала 
вредности pTBARS и активност SOD. Унос OLE у дози од 2000 mg kg-1 изазвао је умерен 
хипотензивни ефекат само код пацова са спонтаном хипертензијом, указујући на 
одсуство штетних хемодинамских дејстава након предозирања код оба соја пацова, али 
не би требало занемарити прооксидативно дејство његових високих доза у 
хипертензивном организму.  
(Примљено 18. фебруара, ревидирано 26. марта, прихваћено 27. марта 2014) 
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